PARIS, Sept. 9 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced today that it has acquired all the assets of Cyto Pulse Sciences Inc., a US-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment. Electroporation is a very efficient way to allow molecules such as meganucleases to enter any type of cells, with applications ranging from research and bioproduction to agriculture and therapeutics.

The transaction value of $2.2 million was paid in cash and closed on September 2, 2010.

This acquisition provides Cellectis with:

• Recurrent licensing income (>$600k in 2009) from HybrimuneTM, Cyto Pulse's electrofusion technology that is licensed broadly to antibody companies; already available from Cellectis bioresearch
• A range of electroporation instruments for in vitro and in vivo delivery of nucleic acids and proteins, including DNA vaccines
• An unlimited access to Pulse Agile®, one of the safest electroporation technologies for use in combination with Cellectis' meganuclease platform

"Cyto Pulse's assets are a great strategic fit for Cellectis," said Andre Choulika, Cellectis' CEO. "As we announced last year, part of our development strategy is to acquire businesses that complement our existing meganuclease platform and that can be leveraged across all aspects of our business, from research through to therapeutics. We saw such an opportunity in the technologies at Cyto Pulse Sciences Inc. and look forward to unlocking the value of these assets."

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over Euro 70 million in funding since inception.

More information at www.cellectis.com

Follow Cellectis on twitter at www.twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

SOURCE Cellectis

Back to top

RELATED LINKS
http://www.cellectis.com